Board of Directors
PETER G. TOMBROS
Chairman of the Board
Professor and Executive in Residence in the Eberly College of Science B.S. / M.B.A. Program at Pennsylvania State University
MICHAEL W. BONNEY, B.A.
President and Chief Executive Officer, Cubist Pharmaceuticals, Inc.
JAMES G. GRONINGER, M.B.A.
Chief Executive Officer, LBS Technologies and President, The Bay South Company
DONALD E. KUHLA, Ph.D.
Director, Albany Molecular Research, Inc.
FRANCOIS NADER, M.D., M.B.A.
President and Chief Executive Officer, NPS Pharmaceuticals, Inc.
RACHEL R. SELISKER, C.P.A.
President, Seamark Advisors LLC
CALVIN R. STILLER, M.D.
Chairman and Chief Executive Officer, Stilco Corporation and BioQuest Innovations Inc.
PETER G. TOMBROS
Chairman of the Board
Professor and Executive in Residence in the Eberly College of Science B.S. / M.B.A. Program at Pennsylvania State University
Mr. Tombros has served as a director since 1998 and in January 2008 was appointed as Chairman of the Board. Prior to January 2008, he served as lead director since May 2006. Since 2005, Mr. Tombros has served as professor and executive in residence in the Eberly College of Science BS/MBA Program at Pennsylvania State University. Prior to that he was chairman of the board and chief executive officer of VivoQuest, a private biopharmaceutical company. From 1994 until June of 2001, Mr. Tombros served as president, chief executive officer and director of Enzon Pharmaceuticals, Inc., a publicly held biopharmaceutical company. Prior to joining Enzon, Mr. Tombros spent 25 years with Pfizer Inc., a global healthcare company in a variety of senior management positions including vice president of marketing, senior vice president and general manager of the Roerig Pharmaceuticals Division, executive vice president of Pfizer Pharmaceuticals Division, director of Pfizer Pharmaceuticals Division, vice president of corporate strategic planning, and vice president, corporate officer, Pfizer Inc. Mr. Tombros serves on the board of directors of Alpharma Inc., Cambrex, PharmaNet Development Group, Inc. and Protalex, Inc. Mr. Tombros received B.S. and M.S. degrees from Pennsylvania State University and an M.B.A. degree from the University of Pennsylvania Wharton Graduate School of Business.
MICHAEL W. BONNEY
President and CEO, Cubist Pharmaceuticals, Inc.
Mr. Bonney has served as a director since January 2005. Mr. Bonney has served since June 2003 as the president and chief executive officer and as a member of the Board of Directors of Cubist Pharmaceuticals, Inc., a public biopharmaceutical company. From January 2002 to June 2003, he served as its president and chief operating officer. From 1995 to 2001, he held various positions at Biogen, Inc., a public biopharmaceutical company, including vice president, sales and marketing from 1999 to 2001. Prior to that, Mr. Bonney held various positions in sales, marketing and strategic planning at Zeneca Pharmaceuticals, ending his eleven-year career there serving as national business director. Mr. Bonney has a B.A. in Economics from Bates College.
JAMES G. GRONINGER, M.B.A.
Chief Executive Officer, LBS Technologies and President, The Bay South Company
Mr. Groninger has served as a director since 1988. In February 2002, Mr. Groninger was appointed chief executive officer of LBS Technologies, Inc., a private biotechnology company focusing on a RNA amplification and cellular therapy. Mr. Groninger founded in January 1995 and is president of The Bay South Company, a Richmond, Virginia-based provider of financial advisory and investment banking services. From 1988 through 1994, he served as a managing director, investment banking division, of PaineWebber Incorporated. Mr. Groninger is a member of the board of directors of Cygne Designs, Inc., a publicly held company; Layton BioScience, Inc., LBS Technologies, Inc. and Expression Pathology, Inc., private biotechnology companies. Mr. Groninger received a B.S. from Yale University, an M.B.A. degree from Harvard Business School and has been certified with C.P.A. and C.F.A. designations.
DONALD E. KUHLA, Ph.D.
President and Chief Operating Officer, Albany Molecular Research, Inc.
Dr. Kuhla has served as a director since 1991. From 1998 to January 2004, Dr. Kuhla was president and chief operating officer of Albany Molecular Research, Inc., a chemical contract research organization. Dr. Kuhla continues to serve AMRI as a director. From 1994 through 1998 Dr. Kuhla was vice president of Plexus Ventures, Inc., a business consulting firm. From 1990 to 1994 Dr. Kuhla held senior management positions with two venture capital-backed, biotechnology startup companies. His early career was spent in research and development and operations management positions with Pfizer Inc. and Rorer Group, Inc., his last position at Rorer being senior vice president of operations. Dr. Kuhla received a Ph.D. in organic chemistry from Ohio State University.
FRANCOIS NADER, M.D., M.B.A.
President and Chief Executive Officer, NPS Pharmaceuticals, Inc.
Dr. Nader has served as a director since January 2008. He has served as our Chief Executive Officer and President since March 2008. Prior to that, he served as our Chief Commercial Officer and Executive Vice President since July 2007. Prior to that, he served as our Chief Medical and Commercial Officer since June 2006. Prior to joining NPS, Dr. Nader served Care Capital, LLC as a venture partner for the firm and as Chief Medical Officer for its Clinical Development Capital unit from July 2005 to June 2006. From 2000 to July 2005, Dr. Nader served as Senior Vice President, Integrated Healthcare Markets and Senior Vice-President, North America Medical and Regulatory Affairs with Aventis Pharmaceuticals. Prior to that, Dr. Nader held similar executive positions with Hoechst Marion Roussel and Marion Merrell Dow and was head of global commercial operations for Pasteur Vaccines, a division of Rhone Poulenc. Dr. Nader received a French State Doctorate in Medicine from St. Joseph University and a Physician Executive MBA from the University of Tennessee.
RACHEL R. SELISKER
President, Seamark Advisors LLC
Ms. Selisker has served as a director since January 2005. Ms. Selisker is president of Seamark Advisors LLC and has provided financial consulting and appraisal services in the healthcare sector since June 2007. She served from March 2006 to June 2007 as chief financial officer of AAIPharma Inc., a privately held contract research organization. From January 2001 to March 2006 she served as a managing director in the Raleigh, North Carolina office of Thompson Clive & Partners Inc., a venture capital firm based in London, where she focused on the life sciences sector. She served from July 1987 to February 2000 as the chief financial officer, and from February 2000 to January 2001 as senior vice president, global shared services, of Quintiles Transnational Corp., a publicly held global contract research organization. Ms. Selisker also served as director of Quintiles Transnational Corp. from November 1995 to February 2000. Ms. Selisker was a supervisor and staff accountant with the national accounting firm of Oppenheim, Appel, Dixon & Co. in Raleigh, North Carolina, from 1981 to 1987. She is a certified public accountant with extensive public accounting experience from 1976, when she graduated with her accounting degree from Wake Technical College in Raleigh, North Carolina until 1987, when she joined Quintiles.
CALVIN R. STILLER, M.D.
Chairman and Chief Executive Officer, Stilco Investments Limited
Dr. Stiller has served as a director since the closing of our acquisition of Allelix Biopharmaceuticals, Inc. in December 1999; he had served on the board of Allelix since April 1999. Dr. Stiller is chairman of the board and chief executive officer of Stilco Corporation and BioQuest Innovations Inc. From 1996 to 2005, Dr. Stiller served as chairman and chief executive officer of Canadian Medical Discoveries Fund. Dr. Stiller served as the chief of the Multi-Organ Transplant Service at the University Hospital in London, Ontario from 1984 through 1996. He is professor emeritus of medicine at the University of Western Ontario. Dr. Stiller was the chairman of the Ontario Research and Development Challenge Fund and is a cofounder and director of MaRS Discovery District, and the Ontario Institute for Cancer Research. He serves as a director of Residential Retirements REIT and Vasogen Corporation. Dr. Stiller received an M.D. degree from the University of Saskatchewan.